Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Rhodes CJ, Im H, Cao A, Hennigs JK, Wang L, Sa S, Chen PI, Nickel NP, Miyagawa K, Hopper RK, Tojais NF, Li CG, Gu M, Spiekerkoetter E, Xian Z, Chen R, Zhao M, Kaschwich M, Del Rosario PA, Bernstein D, Zamanian RT, Wu JC, Snyder MP, Rabinovitch M. Rhodes CJ, et al. Among authors: del rosario pa. Am J Respir Crit Care Med. 2015 Aug 1;192(3):356-66. doi: 10.1164/rccm.201408-1528OC. Am J Respir Crit Care Med. 2015. PMID: 26030479 Free PMC article.
Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension.
Taylor S, Isobe S, Cao A, Contrepois K, Benayoun BA, Jiang L, Wang L, Melemenidis S, Ozen MO, Otsuki S, Shinohara T, Sweatt AJ, Kaplan J, Moonen JR, Marciano DP, Gu M, Miyagawa K, Hayes B, Sierra RG, Kupitz CJ, Del Rosario PA, Hsi A, Thompson AAR, Ariza ME, Demirci U, Zamanian RT, Haddad F, Nicolls MR, Snyder MP, Rabinovitch M. Taylor S, et al. Among authors: del rosario pa. Am J Respir Crit Care Med. 2022 Oct 15;206(8):1019-1034. doi: 10.1164/rccm.202102-0446OC. Am J Respir Crit Care Med. 2022. PMID: 35696338 Free PMC article.
Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.
Saito T, Miyagawa K, Chen SY, Tamosiuniene R, Wang L, Sharpe O, Samayoa E, Harada D, Moonen JAJ, Cao A, Chen PI, Hennigs JK, Gu M, Li CG, Leib RD, Li D, Adams CM, Del Rosario PA, Bill M, Haddad F, Montoya JG, Robinson WH, Fantl WJ, Nolan GP, Zamanian RT, Nicolls MR, Chiu CY, Ariza ME, Rabinovitch M. Saito T, et al. Among authors: del rosario pa. Circulation. 2017 Nov 14;136(20):1920-1935. doi: 10.1161/CIRCULATIONAHA.117.027589. Epub 2017 Sep 21. Circulation. 2017. PMID: 28935667 Free PMC article.
Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.
Sweatt AJ, Miyagawa K, Rhodes CJ, Taylor S, Del Rosario PA, Hsi A, Haddad F, Spiekerkoetter E, Bental-Roof M, Bland RD, Swietlik EM, Gräf S, Wilkins MR, Morrell NW, Nicolls MR, Rabinovitch M, Zamanian RT. Sweatt AJ, et al. Among authors: del rosario pa. Chest. 2021 Oct;160(4):1442-1458. doi: 10.1016/j.chest.2021.06.028. Epub 2021 Jun 26. Chest. 2021. PMID: 34181952 Free PMC article.
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Saad F, Del Rosario P, Clarke NW. Saad F, et al. Among authors: del rosario p. Eur Urol. 2024 Jun;85(6):e178-e179. doi: 10.1016/j.eururo.2023.11.015. Epub 2023 Dec 1. Eur Urol. 2024. PMID: 38042647 No abstract available.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: del rosario pm. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: del rosario pm. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Roubaud G, Özgüroğlu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K. Roubaud G, et al. Among authors: del rosario p. Eur J Cancer. 2022 Jul;170:73-84. doi: 10.1016/j.ejca.2022.04.016. Epub 2022 May 19. Eur J Cancer. 2022. PMID: 35598359 Free article. Clinical Trial.
13 results